Role of Connexin47 mutations in primary lymphedema
Role of Connexin47 mutations in primary lymphedema
批准号:
8677486
负责人:
JANIS M BURT
金额:
$18.94万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-04-04 至 2016-03-31
关键词:
AblationAdultAffectAnimal ModelArteriesBlood VesselsCellsChylothoraxConnexin 43ConnexinsDefectDevelopmentDietary FatsDiseaseDisease modelDockingDominant-Negative MutationEffectivenessEmbryonic DevelopmentEnsureFamilyFluid BalanceFunctional disorderFutureGap JunctionsGenesGoalsHumanImmune System DiseasesInflammationInflammatoryInflammatory Bowel DiseasesInheritedIntercellular FluidKnockout MiceKnowledgeLeadLifeLocationLymphLymphaticLymphatic DiseasesLymphatic Endothelial CellsLymphatic SystemLymphatic vesselLymphedemaMetabolic DiseasesMissense MutationModelingMolecularMorphogenesisMorphologyMusMutateMutationNatureNormal tissue morphologyPathway interactionsPersonsPhasePhenotypePhysiologicalPhysiologyPlayProteinsRefluxResearch PersonnelRoleSecondary toSignal TransductionStructureTestingVenousWorkabsorptionarteriolebasedisease phenotypeextracellularimmune functioninsightloss of functionloss of function mutationmouse modelmutant mouse modelnovelnovel strategiesnull mutationpreventprimary lymphedemapublic health relevancesmall moleculetheories
中文摘要
描述(由申请人提供):该项目的目标是探索某些形式的原发性淋巴水肿是由连接蛋白(Cx)基因突变引起的瓣膜形成缺陷引起的。淋巴(Ly)系统的功能对于正常的组织液平衡、免疫功能、饮食脂肪的吸收和运输至关重要,淋巴阀确保淋巴液向前移动,而不是异常地聚集或回流。Ly系统的缺陷,包括那些可能涉及有缺陷或不合格的瓣膜,导致许多先天性和后天性疾病。特别是淋巴水肿,是一种潜在的使人衰弱的疾病,其中间质液异常积聚,估计会影响
英文摘要
DESCRIPTION (provided by applicant): The goal of this project is to explore the idea that some forms of primary lymphedema are caused specifically by defective valve formation resulting from mutations in Connexin (Cx) genes. Lymphatic (Ly) system function is essential for normal tissue fluid balance, immune function, and absorption and transport of dietary fat, and valves ensure that lymph moves forward rather than abnormally collecting or refluxing. Defects of the Ly system, including those that may involve defective or incompetent valves, lead to a number of congenital and acquired disorders. Lymphedema, in particular, is a potentially debilitating disorder in which interstitial fluid abnormally accumulates and is estimated to affect
as many as 140-250 million people worldwide. Despite progress in identifying key genes involved in Ly development, the molecular mechanisms controlling the morphogenesis of Ly valves remain poorly understood. Thus, increased knowledge about the molecular pathways functioning during Ly valve development provides an excellent opportunity for new approaches to prevent or treat lymphatic disorders such as lymphedema. Recently, a new key player in valve development was discovered: Cxs - a family of related proteins which assemble into gap junction intercellular channels, structures that allow for the direct transfer of small molecules between adjacent cells. Previous vascular work focused on the role of Cxs in the development, remodeling, and physiology of arteries and arterioles. However, we have discovered that three Cxs (Cx37, Cx43, and Cx47) are expressed in the Ly endothelial cells of developing Ly vessels and that these proteins become progressively enriched at Ly valves (and venous valves). Using global Cx knockout mice, Cx37 and Cx43 were shown to be critical for Ly valve formation. Although Cx47 was shown to be mutated in some families with primary lymphedema, nothing is known about the role of Cx47 in Ly development or function. Based on the location of the Cx47 missense mutations in highly conserved Cx extracellular loops, we propose that the mutations are dominant negative in nature and result in primary lymphedema through a combined inhibition of wild-type Cx47 and Cx43 (which colocalize at valves), leading to defective valve development. In this proposal, we will compare the effects, in mouse models, of a Cx47 null mutation and a putative Cx47 dominant negative mutation that causes lymphedema in humans. The effects of these mutations on Ly valve formation, Ly function, and development of lymphedema will be assessed in the mice. In addition, the effects of a combined null mutation of Cx47 and Cx43 will be determined as another test of the theory that both Cx47 and Cx43 must be inhibited for a severe disease phenotype. The mouse lines generated in this project will provide valuable new animal models for the study of primary lymphedema and allow for a better understanding of how Ly dysfunction initiates or contributes to disease. In addition, the mouse models will be useful for future studies aimed at identifying the local physiological conditions that contribute to secondary lymphedema.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Phosphorylation and gating of cardiac connexin channels
-
批准号:9078759
-
项目类别:
-
资助金额:$39.57万
-
财政年份:2016
-
负责人:JANIS M BURT
-
依托单位:
Role of Connexin47 mutations in primary lymphedema
-
批准号:8831729
-
项目类别:
-
资助金额:$18.65万
-
财政年份:2014
-
负责人:JANIS M BURT
-
依托单位:
Role of Gap Junctions in Blood Vessel Assembly
-
批准号:8267618
-
项目类别:
-
资助金额:$37.55万
-
财政年份:2009
-
负责人:JANIS M BURT
-
依托单位:
Role of Gap Junctions in Blood Vessel Assembly
-
批准号:7901514
-
项目类别:
-
资助金额:$37.55万
-
财政年份:2009
-
负责人:JANIS M BURT
-
依托单位:
Role of Gap Junctions in Blood Vessel Assembly
-
批准号:7750472
-
项目类别:
-
资助金额:$38.88万
-
财政年份:2009
-
负责人:JANIS M BURT
-
依托单位:
Role of Gap Junctions in Blood Vessel Assembly
-
批准号:8452686
-
项目类别:
-
资助金额:$39.62万
-
财政年份:2009
-
负责人:JANIS M BURT
-
依托单位:
GAP JUNCTIONS IN VASCULAR SMOOTH MUSCLE--GROWTH CONTROL
-
批准号:6030845
-
项目类别:
-
资助金额:$20.91万
-
财政年份:1997
-
负责人:JANIS M BURT
-
依托单位:
Gap Junctions in Vascular Smooth Muscle: Growth Control
-
批准号:8209153
-
项目类别:
-
资助金额:$37.88万
-
财政年份:1997
-
负责人:JANIS M BURT
-
依托单位:
Gap junctions in Vascular Smooth Muscle: growth control
-
批准号:7039119
-
项目类别:
-
资助金额:$33.15万
-
财政年份:1997
-
负责人:JANIS M BURT
-
依托单位:
Gap junctions in Vascular Smooth Muscle: growth control
-
批准号:6929542
-
项目类别:
-
资助金额:$33.86万
-
财政年份:1997
-
负责人:JANIS M BURT
-
依托单位:
Gap junctions in Vascular Smooth Muscle: growth control
-
批准号:7575801
-
项目类别:
-
资助金额:$32.21万
-
财政年份:1997
-
负责人:JANIS M BURT
-
依托单位:
GAP JUNCTIONS IN VASCULAR SMOOTH MUSCLE--GROWTH CONTROL
-
批准号:6194449
-
项目类别:
-
资助金额:$26.11万
-
财政年份:1997
-
负责人:JANIS M BURT
-
依托单位:
Gap Junctions in Vascular Smooth Muscle: Growth Control
-
批准号:8049457
-
项目类别:
-
资助金额:$37.88万
-
财政年份:1997
-
负责人:JANIS M BURT
-
依托单位:
Gap Junctions in Vascular Smooth Muscle: Growth Control
-
批准号:8583331
-
项目类别:
-
资助金额:$37.12万
-
财政年份:1997
-
负责人:JANIS M BURT
-
依托单位:
GAP JUNCTIONS IN VASCULAR SMOOTH MUSCLE--GROWTH CONTROL
-
批准号:6537333
-
项目类别:
-
资助金额:$26.51万
-
财政年份:1997
-
负责人:JANIS M BURT
-
依托单位:
GAP JUNCTIONS IN VASCULAR SMOOTH MUSCLE--GROWTH CONTROL
-
批准号:2735394
-
项目类别:
-
资助金额:$20.07万
-
财政年份:1997
-
负责人:JANIS M BURT
-
依托单位:
Gap junctions in Vascular Smooth Muscle: growth control
-
批准号:7185786
-
项目类别:
-
资助金额:$32.21万
-
财政年份:1997
-
负责人:JANIS M BURT
-
依托单位:
Gap Junctions in Vascular Smooth Muscle: Growth Control
-
批准号:8386975
-
项目类别:
-
资助金额:$36.06万
-
财政年份:1997
-
负责人:JANIS M BURT
-
依托单位:
Gap junctions in Vascular Smooth Muscle: growth control
-
批准号:7367201
-
项目类别:
-
资助金额:$32.21万
-
财政年份:1997
-
负责人:JANIS M BURT
-
依托单位:
GAP JUNCTIONS IN VASCULAR SMOOTH MUSCLE--GROWTH CONTROL
-
批准号:6389722
-
项目类别:
-
资助金额:$26.11万
-
财政年份:1997
-
负责人:JANIS M BURT
-
依托单位:
海外基金